$TDOC

Teladoc Health's shares skyrocketed nearly 140% last year. So far in 2021, though, the stock is down close to 30%.
The average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives TDOC stock a score of 29 out of a possible 100. That rank is mainly influenced by a short-term technical score of 10. TDOC's rank also includes a long-term technical score of 13. The fundamental score for TDOC is 65.
In addition to the average rating from Wall Street analysts, TDOC stock has a mean target price of $208.88. This means analysts expect the stock to gain 48.25% over the next 12 months.

I think TDOC is absolutely here to stay.
Telehealth will grow, and beyond Telehealth, virtual care in general.
Chronic disease management, I think it was a good acquisition for Teladoc. I thought it brought a good platform into its lineup, and there's a great opportunity for cross-selling there.
-
After a long battle to hold its price since late February TDOC had finally formed a falling wedge on the daily chart.
It’s starting to look very clean here for a continuation up.
A clean break on the falling wedge.
RSI breaking above 50
& the MACD curling
I suggest keeping this on your watchlist.
- Factor Four